The Herbert Irving Comprehensive Cancer Center participates in a wide range of innovative, feasibility orproof of principle trials originating from its research programs and initiated by institutional Pis. Enrollment inthese studies has been maintained throughout the last grant period. The conduct of these studies issupported by research nursing and data management provided by the Clinical Research ManagementOffice (CRMO). Research Nursing focuses solely on the eligibility, consenting and management of patientson clinical trials. In addition to its participation in the scope of high-priority clinical trials, Herbert IrvingComprehensive Cancer Center has conducted a series of innovative phase I trials of cancer vaccines andimmunotherapy that have provided important information on the mechanisms and clinical efficacy of theseagents. There is an increasing emphasis on interaction between basic science and clinical research asexemplified by ongoing translational studies in breast cancer and lymphoma. Expanded support for ourparticipation in high priority and innovative trials is requested.The projected operating budget for Protocol Specific Research Support is $352,247, of which we arerequesting 100% support from the CCSG.
Showing the most recent 10 out of 331 publications